- Home
- TARS vs FLYW Comparison
TARS vs FLYW Comparison
Compare TARS & FLYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | FLYW |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TARS | FLYW |
|---|---|---|
| Price | $71.93 | $19.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $89.00 | $16.21 |
| AVG Volume (30 Days) | 668.4K | ★ 2.0M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.21 | ★ 450.00 |
| EPS | N/A | ★ 0.03 |
| Revenue | $451,360,000.00 | ★ $623,025,000.00 |
| Revenue This Year | $56.43 | $19.68 |
| Revenue Next Year | $30.19 | $15.25 |
| P/E Ratio | ★ N/A | $647.33 |
| Revenue Growth | ★ 146.71 | 26.59 |
| 52 Week Low | $48.20 | $10.55 |
| 52 Week High | $85.25 | $19.73 |
Technical Indicators
Market Signals| Indicator | TARS | FLYW |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 62.60 |
| Support Level | $60.95 | $13.34 |
| Resistance Level | $74.39 | N/A |
| Average True Range (ATR) | 3.06 | 0.63 |
| MACD | 0.54 | 0.15 |
| Stochastic Oscillator | 95.61 | 84.21 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.